Crizotinib (Xalkori) Granted Regular FDA Approval for Treatment of Lung Cancer

The FDA has granted crizotinib regular approval for the treatment of patients with metastatic anaplastic lymphoma kinase -positive non-small-cell lung cancer , as detected by an FDA-approved test.

http://www.pharmscope.com/news/DailyDetail.cfm?chosen=68045